PLAMA Developers to join India Homes show Kingdomwide

Updated 29 November 2012

PLAMA Developers to join India Homes show Kingdomwide

PLAMA Developers Ltd. is featuring residential projects ranging from top-of-the-line luxury apartments in Bangalore and Kozhikode to premium residential apartments in Trichur and Mangalore at the India Homes 2012 Kingdomwide — Nov. 29 and 30 in Dammam (Cobra Park), Dec. 3 and 4 in Jeddah (Hotel Trident) and Dec. 6 and 7 in Riyadh (Al Yamama Resort & Park).
PLAMA Developers Ltd. has constructed and delivered more than a dozen residential projects in Mangalore City and has earned the reputation of market leader in terms of its construction quality, customer service and delivery schedules. PLAMA is developing projects in Trichur, Kozhikode and Bangalore. With other cities being added soon, the company is looking at establishing itself as one of the leading residential property builders in South India.
PLAMA Developers Ltd. is one of the very few real estate companies in the country to have a combination of ISO certifications ISO 9001:2008 (Quality Management System), ISO 14001:2004 (Environmental Management System), ISO 18001:2007 (Occupational Health and Safety Management Systems). It has one of the best legal systems, transparent documentation and association with firms like D&B and Crisil for services, ratings and certifications.
With more than 1 million square feet of home space delivered, the company intends to separate itself from the competition with consistency in construction quality, customer service, delivery schedules and transparent documentation.
With more than two decades of experience in residential project development Founder Chairman and MD P.M.A. Razak always had a clear vision to transform the way people perceive quality in real estate sector in India. Since its inception, the company has always strived for best practices, benchmark quality, customer first approach, uncompromising business ethics, transparency & finest customer service.
Its portfolio of residential projects is spread across various cities, including Mangalore, Bangalore, Kozhikode and Trichur.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.